EMA Starts Review Of Ixchiq Following Reports Of Serious Adverse Events In Elderly People

May 7 (Reuters) - EMA:

• EMA STARTS REVIEW OF IXCHIQ (LIVE ATTENUATED CHIKUNGUNYA VACCINE)

• EMA: STARTED REVIEW OF IXCHIQ (A LIVE ATTENUATED CHIKUNGUNYA VACCINE) FOLLOWING REPORTS OF SERIOUS ADVERSE EVENTS IN ELDERLY PEOPLE

• EMA: IXCHIQ VACCINE MUST NOT BE USED IN PEOPLE 65 YEARS AND ABOVE WHILE REVIEW IS UNDERWAY - WEBSITE

• EMA: MANY PEOPLE AFFECTED ALSO HAD OTHER ILLNESSES, EXACT CAUSE OF ADVERSE EVENTS & RELATIONSHIP WITH VACCINE NOT YET DETERMINED

• EMA: IXCHIQ VACCINATION CAN CONTINUE IN PEOPLE UNDER 65 YEARS OF AGE, IN ACCORDANCE WITH OFFICIAL RECOMMENDATIONS

• EMA: SO FAR 17 SERIOUS ADVERSE EVENTS, INCLUDING 2 CASES OF DEATH, REPORTED WORLDWIDE IN PEOPLE AGED BETWEEN 62 AND 89 YEARS WHO RECEIVED IXCHIQ